<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences

Find me on:

Recent Posts

Now Available: Electrophysiology Laboratory Services featuring DANTEC Keypoint Focus

Posted by MD Biosciences on Jul 12, 2018 11:00:00 AM

 MB Biosciences is proud to announce our newly established electrophysiology capabilities suited for preclinical neuropathy research! Our lab has acquired the cutting-edge Dantec KEYPOINT Focus tool utilized to measure electrophysiological action potentials. Our scientists have applied these new capabilities in the assessment of Muscle Action Potential (measuring signals from the nerve to muscle) in rodent models of peripheral nerve injury. Using these capabilities, we can measure nerve regeneration, degeneration and protection in response to various treatments. This technology can be further applied to non-rodent species such are our pig translational pain models. Additionally, we are now offering measurement capabilities for Motor Action Potential with a specialized Renovo Neural paradigm—particularly useful for studies of EAE, MS, spinal cord injuries and CNS pain. Application of these capabilities specifically to EAE and MS models provide valuable insights into multiple areas of compound efficacy. View the graphs below to learn more about the ways in which using intraoperative techniques applied in the brain, peripheral nerve surgeries and spine has led us to developing models for monitoring impairment in neural activity. By empirically evaluating neural diseases and their physiological symptoms, we can effectively offer precise measurements for drug effect and treatment options.


To learn more about how this technology can be applied to specific study needs, please contact us.

 

In-vivo neurophysiology

 

A                                             B                                                  C

PIC1-1PIC22-1PIC33-1

Figure 1. A) CNS model - Transcranial electric motor evoked potentials (tcMEPs) were recorded from the bilateral tibialis anterior (TA) muscles using paired subdermal needle electrodes. TcMEP stimulating electrodes were placed anterior to the C3 and C4 scalp positions. B) Pain and sensory model - Somatosensory evoked potential (SSEP) - electrodes were placed along the medial aspect of each ankle at the malleoli for bipolar stimulation of the posterior tibial nerves (PTN). Somatosensory evoked potentials (SSEP) were recorded over the cerebral cortex using subdermal needle electrodes placed posterior to the C3 and C4 scalp positions. Recording electrodes were referenced to the FPz position on forehead. C) PNS model - Compound muscle action potential (CMAP) - recorded from the tibialis anterior muscle using paired subdermal needle electrodes. Stimulating electrodes were placed along the sciatic notch. Data were recorded from a Sprague Dawley rat.

   A                                              B                                            C                                               

PIC4-1PIC5-1Picture3

 

Figure 2: tcMEP Recordings from TA muscle in a multiple sclerosis model. A A healthy potential recorded from naive mouse (C57). B) Desynchronized potential recorded from a mouse treated with MOG demonstrating a clinical paralysis score of 1-2 (mild paralysis). Note multiple picks of potential, late latency for the main potential and extended duration of the total event. C) Small and weak potential recorded from a mouse treated with MOG demonstrating a clinical paralysis score of 3-4 (moderate paralysis).

Read More

Topics: Pain, neuropathic pain, preclinical research, Electrophysiology

Expanding Our Selection of Cutting-Edge CLIA and GLP Capabilities: BD LSR Fortessa™ Flow Cytometer

Posted by MD Biosciences on Jun 22, 2018 11:03:31 AM

MD Biosciences is proud to announce a recent addition to our extensive laboratory services and capabilities: The BD LSR FortessaTM X-20 Flow Cytometer offers the flexibility to support multiparametric (16+ color) analyses with advanced performance and consistency. These capabilities provide increased functionality for applications in preclinical, translational and clinical programs such as immunophenotyping of complex cellular populations, and analysis of cellular activation and proliferation states. Contact us to learn about our flow cytometry capabilities or discuss a study proposal with our scientific team! 

44
Read More

Topics: clinical research, preclinical research, translational research, Biotechnology, immunophenotyping, flow cytometry

MDB Receives 2018 Progress MN Award For Industrial & Economic Development In The Pharma & Biotech Sector Through US Minnesota-Based Site

Posted by MD Biosciences on Apr 6, 2018 11:57:40 AM

Oakdale, Minnesota USA

Nominated via the Minnesota State Dept. Of Employment and Economic Development (DEED), the Progress MN award, offered by Finance & Commerce, recognizes innovative companies that have provided major contributions to business, industrial growth and economic development in innovative and unique ways.

4FrontComplex

MD Biosciences US-site at the 4Front Technology & Office Campus in Oakdale, MN.

 

Taken from Finance and Commerce Website:

https://finance-commerce.com/2018/04/progress-mn-md-biosciences-inc/

 April 6, 2018

 

Eddie Moradian, CEO of the family-owned MD Biosciences Inc., moved to Minnesota in 2008 from Switzerland to take over the company’s American operations.

Headquartered in Switzerland, MD Biosciences operates facilities and laboratories in that country, Israel and Minnesota.

The Minnesota location provides MD Biosciences with a central location and a highly dedicated and educated pool of researchers, health care centers and universities.

The company operates early-stage drug discovery and development laboratories in Minnesota. Labs at the two other locations often participate together in collaborative or fee-for-service pharmaceutical projects, Moradian said.

On a second front, MD Biosciences works closely with pharmaceutical and clinical laboratories in developing advanced clinical diagnostic tools and research products for inflammation, neuro-inflammation, immunological and oncological disease areas.

MD Biosciences has an in-depth expertise and scientific platform that attracts “novel” drug development work in the neurological, inflammatory and oncological disease areas, he said.

Such collaborations, along with internal developments, have resulted in a pipeline of non-opioid compounds for neuropathic pain, an advanced cancer program and blood-based diagnostic tool for a specific cancer, currently in clinical trials.

In 2016, Moradian partnered with Slumberland in the creation of an advanced, multi-technological incubator in Oakdale. “Incubology” offers dry and wet laboratory space, clean rooms and office space to companies in various areas, include biomolecule production, diagnostic processes, medical devices, nanotechnology and chemical synthesis.

“We believe that Incubology will soon grow to be an important regional anchor and seeding ground for new companies and technologies,” he said, “We are truly excited about what the future may bring.”

 

 

About MD Biosciences:

MD Biosciences is a leading provider of preclinical, translational and clinical-phase contract research services.  Established in 1991, MDB provides expertise and services in areas including cancer, cardiovascular, metabolic, inflammatory and neurological conditions including pain-associated disease as well as surgical procedures. Through collaborations with pharmaceutical and medical device pioneers, MDB develops innovative therapeutics and diagnostic assays. Each scientist at MDB is highly specialized, and has an in-depth understanding of a variety of disease mechanisms and how to modulate them. This expertise, strengthened with over 10 years of pharmaceutical efficacy experience, brings value to drug development programs whether the focus is on new therapies or repositioning approved, expiring or failed therapies. Furthermore, MDB's clinical services operate at state of the art laboratories staffed with highly experienced scientists and technicians utilizing the newest and most advanced equipment available. All clinical work is performed according to CLIA standards, and may include assay development and validation, protocol design, sample archiving, and biomarker analysis services.

 

About Incubology:

Incubology was founded to bring technology start-ups together in a shared environment. Members have the benefit of dedicated lab and office space in close proximity to other entrepreneurs from diverse disciplines including biotech, pharma, device, nano and chem. With innovative thinkers from a variety of tech industries in one setting, the opportunity for shared business resources and services is a definite advantage over single-unit space. And as part of a growth-oriented campus, the possibilities for the future are endless.

www.incubology.com

 

About Finance and Commerce:

Finance and Commerce is the only daily newspaper devoted exclusively to business in the Twin Cities (MinneapolisSaint Paul) of Minnesota. Founded in 1887, it provides extensive coverage of Twin Cities business news in the areas of real estate, construction, technology, banking, energy, health care and advertising. It is the official newspaper for Hennepin County and the City of Minneapolis.

https://finance-commerce.com

 

For more information, please contact MD Biosciences at: info-us@mdbiosciences.com 

Read More

Topics: Biomarkers, drug development, clinical research, clinical diagnostics, preclinical research, translational research

MDB Recieves OECD-GLP Certification of Histopathology Facilities

Posted by MD Biosciences on Feb 2, 2018 3:02:12 PM

Nes Ziona, Israel & Oakdale, MN, USA

MD Biosciences is pleased to announce OECD Good Laboratory Practices (GLP) Certification for it’s integrated histopathology and IHC facilities located at the Weizmann Science Park in Israel.

 

MD Biosciences Histopathology and IHC laboratories assist sponsors in the identification and development of clinically relevant biomarker assays and novel methods. The laboratories provide services for a wide variety of tissue types such as skin, joint, neuronal or others from human, porcine, rodent and other species. 

 

This GLP certification for Histopathology and Toxicological Pathology follows GLP certification of MD Biosciences’ in vivo Preclinical Animal Research Facilities, as well as recognition according to Clinical Laboratory Improvement Amendment (CLIA) provisions for MD Biosciences Clinical Biomarker and Diagnostics Division.

 GLP-Histology-IHC-Services-Biomarker-Development-Preclinical-Research

 

About MD Biosciences:

MD Biosciences is a leading provider of clinical and preclinical contract research services.  Established in 1991, MDB provides expertise and services in areas including cancer, cardiovascular, metabolic, inflammatory and neurological conditions including pain-associated disease as well as surgical procedures. Through collaborations with pharmaceutical and medical device pioneers, MDB develops innovative therapeutics and diagnostic assays. Each scientist at MDB is highly specialized, and has an in-depth understanding of a variety of disease mechanisms and how to modulate them. This expertise, strengthened with over 10 years of preclinical efficacy experience, brings value to drug development programs whether the focus is on new therapies or repositioning approved, expiring or failed therapies. Furthermore, MDB's clinical services operate at state of the art laboratories staffed with highly experienced scientists and technicians utilizing the newest and most advanced equipment available. All clinical work is performed according to CLIA standards, and may include assay development and validation, protocol design, sample archiving, and biomarker analysis services. 

 

For additional information related to our QC/QA divisions, please email info-us@mdbiosciences.com, Attention: Quality Division.

Read More

Topics: GLP Histopathology

MD Biosciences Announces Launch of Salspera, LLC To Advance Saltikva® (MDB401B) Towards Regulatory Approval As Cancer Immunotherapeutic

Posted by MD Biosciences on Jul 18, 2017 4:26:21 PM

MD Biosciences is proud to announce the launch of Salspera, LLC (www.salspera.com) to advance Saltikva® (MDB401B), a microbial-based immunotherapeutic product targeting cancer, towards regulatory approval. The Salspera team is actively preparing the next clinical study phase following the successful completion of Phase 1 human safety studies. Saltikva® has been presented at high level meetings, including the most recent conference held at the NIH National Cancer Institute. Next generation programs are also advancing through the preclinical pipeline, with the goal of providing a robust palette of specialized attenuated Salmonella-based guided therapies addressing patient needs with personalized “cocktails” and adjunct therapies.

Salspera-Logo.jpg

 

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 

Read More

Topics: Immuno-Oncology

NEW CLINICAL RESEARCH CONSORTIUM PROVIDES INTEGRATED DEVELOPMENT PLATFORM IN MEDICAL ALLEY

Posted by MD Biosciences on Apr 20, 2017 3:20:14 PM

Saint Paul, MN, April 20, 2017     Five leading research organizations have partnered to provide the most comprehensive clinical development platform in the industry. Leveraging their collective expertise, the Center for Diagnostic Imaging (CDI), Medtronic, MD Biosciences, Prism Research, and ThreeWire, have come together to make it easier for life science companies and clinicians to bring lifesaving and life improving products to patients in need. Dubbed the Minnesota Clinical Research Hub, this partnership provides sponsors with a flexible platform for conducting their trials, allowing use of the partners individually and collectively as research needs dictate. Contact MD Biosciences for more details about the MCRH and activities.

 

 

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Read More

Topics: CRO/outsourcing, contract research, Personalized medicine, CLIA

MD Biosciences to present new advances in pig translational models for pain

Posted by MD Biosciences on Apr 20, 2017 2:38:10 PM

 

 MD Biosciences will be presenting its newest advances in translational pig models for pain at this year's SMi Pain Therapeutics Conference to be held in London, UK on May 22-23. Translational models in pigs for the study of pain have become an indispensable tool in drug development. The skin structure of the pig, particularly with respect to its neuronal structure, shows a high degree of similarity to that of humans. This provides a platform in which new therapeutics can be tested to yield results which are highly predictive of human outcomes. MD Biosciences has continuously developed its models to approximate the human condition as closely as possible, bringing its unique capabilities to the drug development process. Please contact MD Biosciences or SMi Group Ltd for conference details.

 

 

Read More

Topics: Pain, in vivo pain models, post-operative pain

MD Biosciences Expands Histology and IHC Capabilities

Posted by MD Biosciences on Mar 1, 2017 1:50:17 PM

         

 

MD Biosciences Expands Histology and IHC Capabilities

New laboratories serving growing activity on clinical assay development and analysis front

 

Weizmann Science Park, Israel, (27 February 2017) - MD Biosciences announces the expansion of its histology and IHC preclinical and clinical services. The expansion encompasses new laboratories at the Nes Ziona facility - featuring an expanded footprint, automation, plus additional new team members.

This expansion accomodates MD Biosciences' growing activity in the development of assays for novel biomarkers in preclinical, translational and clinical applications. MD Biosciences is uniquely positioned to identify and develop biomarker assays as early as preclinical phases and follow these through clinical studies. The laboratory is led by Dr. Avital Schauder and supported by a highly experienced team of scientists.

Screen Shot 2017-02-03 at 1.14.38 PM.png

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 

Contact: Jane Smith

MD Biosciences Inc.
1 Imation Way          
Oakdale, MN 55128
Toll Free: 888-876-3246 or 651-641-2881
Email    

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX

MD Biosciences Announces Facility Expansions

Posted by MD Biosciences on Nov 28, 2016 12:58:26 PM

MD Biosciences Expands into New State-of-the-Art

Research Facilities                 

New Lab_Oakdale.jpg

(New research facilities to play pivotal role in Life Sciences Innovation)

St. Paul, Minn, (11.28.2016) - MD Biosciences announces its moves to new, expanded facilities in the United States and Israel. The larger research facilities will enable MD Biosciences to accommodate its growing clinical and preclinical services, its collaborative research and development activities, plus its growing drug development programs.

The new, purpose-built facilities feature state-of-the-art in vivo and in vitro laboratories, including larger space resources for CLIA proteomic and genomic analyses, and clinical flow cytometry work. The MD Biosciences histology and pathology laboratories have also been expanded to provide more complex GLP capabilities in the CNS, skin, immune-oncology and inflammatory therapeutic areas. To further accommodate specific project requirements - the new facilities also feature extensive Class 100 cleanrooms. 

As part of the new US facility, MD Biosciences will serve as the core anchor for Incubology, Inc., the new science park and incubator facility located in Oakdale, just east of Saint Paul, Minnesota. Incubology will host start-up and established companies from the pharma, medtech, chemistry and healthcare data sectors.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 

Contact: Jane Smith

MD Biosciences Inc.
1 Imation Way          
Oakdale, MN 55128
Toll Free: 888-876-3246 or 651-641-2881
Email    

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX

MD Biosciences Announces License to Colorectal Cancer Markers

Posted by MD Biosciences on Oct 14, 2016 9:53:54 AM

MD Biosciences in-licenses intellectual property assets relating to colorectal cancer diagnostic methods of Bio-Marcare Technologies

cancer-studies.jpg

(Blood-based Colon Cancer Screening Methodology)

October 14, 2016, Weizmann Science Park, Nes Ziona, Israel - MD Biosciences announced today its agreement for the exclusive license rights of all intellectual property assets of Bio-Marcare Technologies, Ltd. that relate to methods for circulating, DNA-based identification of pre-cancerous colorectal polyps and colorectal cancer. This agreement has been reached with Hadasit Medical Research Services and Development Ltd. of the Hadassah Ein Kerem Medical Center in Jerusalem, Israel.

MD Biosciences clinical scientists will be developing the methods towards commercialization at its CLIA clinical laboratories. “We are very excited to move forward with the development of the technology to provide a sensitive and cost-effective method for identifying and monitoring individuals at high risk of colorectal cancer, said Eddie Moradian, Chief Executive Officer of MD Biosciences. “A large percentage of individuals do not readily comply with current colon cancer screening methods and they would readily benefit from our blood-based tests.” 

Development work will be carried out at MD Biosciences Innovalora in Israel in conjunction with the MD Biosciences CLIA Clinical Diagnostics Laboratories in Saint Paul, MN.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX